Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to this Summary (12/06/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Benign Tumors

Added text to state that a report of two patients with retro-orbital infantile hemangioma and arteriopathy suggested a possible new presentation of PHACE syndrome. For patients with proptosis, globe deviation, and strabismus, a magnetic resonance imaging/magnetic resonance angiogram is recommended. Further workup for PHACE may be needed on the basis of central nervous system findings (cited Antonov et al. as reference 32).

Added text to state that a prospective randomized study that compared timolol and propranolol with propranolol reported a decrease in color of the hemangioma in the timolol group but no difference in overall size of the hemangioma between the two treatment groups (cited Li et al. as reference 41).

Added text to state that a meta-analysis that evaluated 5,130 patients from 61 studies concluded that propranolol was more effective and safer than were other treatments for infantile hemangioma (cited Liu et al. as reference 50).

Added text to state that further studies are needed to assess differences between the toxicities of these agents and the toxicities of propranolol. There is some suggestion that the more selective beta-blockers have fewer side effects (cited Bernabeu-Wittel et al. as reference 54).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Special Considerations for the Treatment of Children With Cancer

Next section >
About This PDQ Summary